Bill Weldon serves as Chairman of the Board of Directors for HeartFlow, Inc. He spent more than four decades at Johnson & Johnson, where he began his career as a sales representative, moved to roles of increasing responsibility across business segments, and ultimately led the company through significant expansion and growth as chairman and CEO. In addition to his board position at HeartFlow, he currently serves on the boards of directors of J.P. Morgan Chase & Co., CVS Health, Chubb Corporation and Exxon Mobile Corporation; and the board of trustees of Quinnipiac University.
Casey Tansey joined USVP as a general partner in April 2005. A veteran of the medical device industry, Casey brings over 25 years of entrepreneurial, early-stage medical device and seasoned operating experience to USVP. During his tenure as CEO and President of Epicor Medical from 2001 to 2004, Casey, along with a dedicated team, pioneered a minimally-invasive treatment for atrial fibrillation and transformed the company into a recognized market leader. He led Epicor’s acquisition by St. Jude Medical at a valuation of more than $200 million. Prior to Epicor, Casey was CEO and President of Heartport, a public company that helped pioneer minimally-invasive cardiac surgery which is now a Johnson & Johnson company. Before that, he was with Baxter Edward’s Cardiovascular Division for nearly ten years, holding various sales and marketing positions. During his tenure at Baxter, Casey was involved in launching innovative heart valve products that have grown to be the market leaders.
Charles is a Founder, Chief Scientific Officer, and Member of the Board of Directors of HeartFlow Inc. Previously, he was an Associate professor in the Departments of Bioengineering and Surgery at Stanford University with courtesy faculty appointments in the Departments of Mechanical Engineering and Radiology. He is also currently an Adjunct Professor of Computational Engineering and Sciences at the University of Texas, Austin and a Part-time Professor of Biomedical Engineering at the Technical University of Eindhoven. He is internationally recognized for his pioneering work over the last 30 years in combining computer simulation methods with medical imaging data for patient-specific modeling of blood flow to aid in the diagnosis and treatment of cardiovascular disease. He received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering and M.S. degree in Mathematics from Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University.
Jeffrey Lightcap serves as a Senior Managing Director of HealthCor Partners Management, L.P., a leading growth-oriented private equity fund which invests across all sectors of healthcare. HealthCor Partners is affiliated with HealthCor Management, a successful, research driven, heathcare-focused hedge fund. Prior to joining HealthCor Partners in late 2006, Mr. Lightcap was a Senior Managing Director at JLL Partners, a leading middle-market private equity fund, from 1997 to 2006. Prior to JLL Partners, Mr. Lightcap was a Managing Director at Merrill Lynch & Co., Inc., in the mergers and acquisitions group. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. and briefly at Salomon Brothers. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York in 1981 and an M.B.A. from the University of Chicago in 1985. Mr. Lightcap serves on the board of directors of a number of companies, Careview Communications, Inc., RTI Surgical Inc. (Nasdaq: RTIX), and KellBenx, Inc.
John Farquhar is the President, Chief Executive Officer and Member of the Board of Directors of HeartFlow and brings more than 20 years of experience providing strategic oversight to deliver operational excellence and outstanding performance. Most recently, John served as Vice President and General Manager of the Aortic business at Medtronic. He also served in key leadership roles for Medtronic’s Cardiovascular and Diabetes Groups, including Vice President of the Americas region for the Insulin Pump and Continuous Glucose Monitoring business unit and Vice President for Asia Pacific.
Julie Cullivan has more than 25 years of operational and technical experience across some of the world’s largest cybersecurity and IT brands. She has spent her career helping enterprise software and cloud companies scale their businesses and is a sought-after speaker on diversity and inclusion, security as a boardroom imperative, innovation and building high-impact teams. Most recently, Julie was the Chief Technology and People Officer at Forescout Technologies, and she has held executive roles focused on global sales and business operations at FireEye, Autodesk, McAfee, EMC and Oracle. She also serves on the board of directors for Axon Enterprise, Inc., and has a B.S. degree in Finance from Santa Clara University.
Lonnie Smith joined Intuitive Surgical as President and CEO in June 1997, and currently serves as Chairman of the Board of Directors. During his tenure as CEO, Intuitive Surgical grew from a start-up with no revenue to over one billion dollars in revenue and approximately 1,300 employees. Prior to joining Intuitive Surgical, Mr. Smith was Senior Executive Vice President of Hillenbrand Industries. Mr. Smith joined Hillenbrand in 1978; during his tenure, he was a member of the executive committee, the office of the president and the board of directors. Mr. Smith has also held positions at The Boston Consulting Group and IBM. Mr. Smith receives his B.S.E.E. from Utah State University and an M.B.A. from Harvard Business School.
Tim Barabe brings more than 30 years of experience in the life sciences industry, across a broad range of financial and strategic roles. Most recently, Mr. Barabe served as the chief financial officer and executive vice president at Affymetrix Inc., where he led the company’s financial functions as well as the treasury, investor relations, and information technology departments. For more than 20 years, he held senior international executive roles in finance, general management, and strategic planning at Novartis AG. His roles included chief financial officer of the Sandoz Generics Business Unit, president of the CIBA Vision Corporation Specialty Lens Business Franchise, and group vice president and chief financial officer of CIBA Vision Corporation. Mr. Barabe has a Bachelor of Business Administration in finance from the University of Massachusetts (Amherst) and an MBA from the University of Chicago.
Wayne Riley is the President of the State University of New York (SUNY), Downstate Health Sciences University where he also holds academic rank as Professor of Internal Medicine and of Health Policy & Management. Dr. Riley is a Commissioner of the U.S. Medicare Payment Advisory Commission (MedPAC), Chair of the Board of Directors of the New York Academy of Medicine, President Emeritus of the 150,000-member American College of Physicians, which is the nation’s largest medical specialty organization, and an elected member of the prestigious National Academy of Medicine. From January 2007 until July 2013, Dr. Riley was the 10th President and Chief Executive Officer of Meharry Medical College. Prior, he served as a corporate officer and member of the senior management team as the Vice-President and Vice Dean for Health Affairs and Governmental Relations and Associate Professor of Internal Medicine at the Baylor College of Medicine in Houston, Texas.
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.
Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.